# OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

> **NCT05949021** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mridula George, MD** · enrollment: 30 (actual)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Combination of liposomal doxorubicin

## Key facts

- **NCT ID:** NCT05949021
- **Lead sponsor:** Mridula George, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-07
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05949021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05949021, "OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05949021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*